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Abstract
Background Hemolytic uremic syndrome (HUS) is one of the
most common causes of acute renal failure in children, with
the majority of cases caused by an infection with Shiga toxin-
producing Escherichia coli (STEC). Whereas O157 is still the
predominant STEC serotype, non-O157 serotypes are increas-
ingly associated with STEC-HUS. However, little is known
about this emerging and highly diverse group of non-O157
serotypes. With supportive therapy, STEC-HUS is often self-
limiting, with occurrence of chronic sequelae in just a small
proportion of patients.
Case diagnosis/treatment In this case report, we describe a
16-month-old boy with a highly severe and atypical presenta-
tion of STEC-HUS. Despite the presentation with multi-organ
failure and extensive involvement of central nervous system
due to extensive thrombotic microangiopathy (suggestive of
atypical HUS), fecal diagnostics revealed an infection with the
rare serotype: shiga toxin 2d-producing STEC O80:H2.
Conclusions This report underlines the importance of STEC
diagnostic tests in all children with HUS, including those with
an atypical presentation, and emphasizes the importance of
molecular and serotyping assays to estimate the virulence of
an STEC strain.
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Introduction
Hemolytic uremic syndrome (HUS) is the most common
cause of acute renal failure in children and is diagnosed when
the features of hemolytic anemia and thrombocytopenia are
present simultaneously [1]. In over 90% of pediatric cases,
HUS follows a gastro-intestinal infection with Shiga toxin-
producing Escherichia coli (STEC), previously known by
the name of post-diarrheal or typical HUS, because of its main
characteristic of (bloody) diarrhea [1]. Whereas O157 is still
the predominant STEC serotype, non-O157 serotypes are in-
creasingly associated with STEC-HUS [2]. However, in con-
trast to STEC O157, little is known about this emerging and
highly diverse group of non-O157 serotypes. Thrombotic mi-
croangiopathy (TMA) causing HUS predominantly affects the
renal vasculature. Nevertheless, especially in non-O157
STEC serotypes, extra renal involvement such as central ner-
vous system involvement is described [3]. If symptomatic
treatment is started in time, the recovery of STEC-HUS is
often spontaneously with minimal chronic sequelae [4].
Here we present a case of a 16-month-old boy with an
unusual presentation and rare STEC serotype resulting in a
very severe course of STEC-HUS.
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Case report
A previously healthy 16-month-old boy presented at the emer-
gency department of a general hospital with convulsions and
impaired consciousness. He had a 2-day history of coughing,
vomiting, and lethargy, without signs of fever. Three months
prior, he had a period of non-bloody diarrhea for over a week
after visiting a biological farmer. A detailed medical history of
the patient and family revealed no ingestion of unpasteurized
milk or cheese nor a visit to a foreign country. On physical
examination he exhibited fluctuating levels of alertness. His
respiratory rate was 29/min with oxygen saturation of 97%.
Body temperature (36.4 °C) and blood pressure were normal
(98/60 mmHg) with mildly elevated pulse rate (138 beats per
minute). Examination of the heart, lungs, and abdomen was
unremarkable. Skin examination revealed a pale-looking pa-
tient with petechiae at lower limbs.
Based on clinical suspicion of meningitis or non-
convulsive status epilepticus, ceftriaxone and midazolam
were administered and the patient was transferred to our hos-
pital. Initial laboratory evaluation showed hyperglycemia and
the triad of HUS (Table 1). In the first hours, consciousness
further decreased and the patient was transferred to the pedi-
atric intensive care unit (ICU), where peritoneal dialysis was
initiated due to persistent anuria. Blood and feces samples to
determine the presence of an STEC infection were obtained.
Blood cultures were performed repeatedly and remained neg-
ative during admission. Thrombotic thrombocytopenic purpu-
ra (TTP) was excluded with a normal ADAMTS13 activity
(Table 1). Atypical HUS (aHUS), caused by complement dys-
regulation, was considered because of severity of the presen-
tation, mainly neurological presentation, no recent history of
(bloody) diarrhea, and young age of the patient. Consequently,
the patient received 600 mg of eculizumab. Later incoming
results of additional complement and DNA diagnostics
showed no abnormalities (Table 1).
The following day, fecal diagnostics revealed an STEC
infection, indicating STEC-HUS; real-time polymerase chain
reaction (PCR) was positive for Shiga toxin 2 (Stx2) and
attaching and effacing (eae) genes. In addition, molecular
serotyping using whole genome sequencing revealed the rare
STEC serotype O80:H2, which contained the Stx2d gene and
the rarely in human seen eae ξ gene variant (Table 1) [5].
In the course of admission, the patient developed multiple
signs of severe, extra renal manifestations of TMA. Due to the
severe neurological symptoms, with convulsions and de-
creased consciousness, brain magnetic resonance imaging
(MRI) was performed, showing diffusion restriction of the
deep white matter (Table 1).
On day four of admission, the patient was resuscitated
twice due to post-intubation hypotension and bradycardia,
with rapid recovery of cardiac output. Cardiac biomarkers
were elevated, and retrospectively elevated troponin T levels
and creatine kinase were already present. Echocardiogram re-
vealed a mildly dilated and dysfunctional left ventricle.
Eventually, a follow-up demonstrated a significant improve-
ment in cardiac biomarkers and function.
Pancreas involvement was noticed based on a gradual rise
in serum glucose and elevation of serum amylase and triglyc-
eride concentrations without clinical signs of pancreatitis.
Insulin treatment was needed for 2 weeks.
After 2 weeks, jaundice was observed in combination with
elevated bilirubin levels, without signs of ongoing hemolysis.
Progressive elevation of transaminases was measured, with
normal levels of clotting factors but low serum albumin
(Table 1). Liver biopsy showed extensive signs of cholestasis
without microthrombi, most likely due to sludging or drug-
related effects (Fig. 1).
Eventually, our patient was hospitalized for over 3 months.
Only minimal signs of neurological improvement were ob-
served and over time the patient developed spastic dystonia.
Furthermore, he exhibited persistently decreased levels of
consciousness with frequent periods of severe agitation. The
patient remained anuric for which dialysis was continued.
Nine months after initial presentation, the patient died due to
peritoneal and hemodialysis failure combined with progres-
sive liver failure and further neurological impairment.
Discussion
In this report, we describe a 16-month-old boy with an unusu-
al, severe presentation and course of STEC-HUS due to the
rare Stx2d-producing E. coli O80:H2. STEC-HUS is a com-
mon cause of HUS in childhood and in more than half of the
cases results from an STEC infection with serotype O157.
However, non-O157 serotypes are increasingly associated
with HUS in recent years, most likely due to improvement
of diagnostics [1, 2]. Usually, the majority of STEC-HUS
resolves with no or minimal chronic sequelae.
STEC infection with serotype O80:H2 resulting in HUS
was rarely described up to recently [2, 6–8]. To our knowl-
edge, up till now, this serotype was only found in patients with
HUS in France and this report is the first describing a case in
the Netherlands. In addition, one study from Spain already
described the finding of this serotype in cattle over 10 years
ago. Interesting to note is that there is no direct geographic
connection between the different areas. Hence, the source of
the O80 serotype remains of unknown origin [8].
STEC strains can produce different shiga toxins, respective-
ly Stx1 and Stx2. Within these genotypes, especially the Stx2
gene, there is a wide variety of Stx subtypes, such as Stx2d
which we describe in this Case report [9]. Moreover, the
Stx2d gene is known to cause a more severe course of disease.
This together with the rare eae ξ and the plasmid of the O80:H2
STEC, which showed high resemblance with the previous
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Table 1 Multi-organ involvement
Test At admission Most abnormal value At discharge Normal value
or range
Differential diagnosis
Blood culture Negative Negative
TTP ADAMTS13 activity (%) 91% >65%
STEC-HUS Serology
O157 IgM/G/A Negative
O26 IgM/G/A Negative
PCR Stx1 gene Negative Negative
Stx2 gene Positive Negative
eae gene Positive Negative
WGS Serotype O80:H2
Isolate Stx2d, eae ξ variant
Sequence type ST301
Virulence factors
Stx1gene Negative
Stx2gene Positive
eae Positive
aggR Negative
aatA Negative
aHUS Complement
C3 (mg/l) 874 NA NA 900–1800
C4 (mg/l) 71 NA NA 150–400
Anti factor H autoantibodies Negative
DNA analysis
Factor H No pathogenic variation
Factor I No pathogenic variation
Factor B No pathogenic variation
C3 No pathogenic variation
MCP No pathogenic variation
CFHR 1–5 No pathogenic variation
DGKE No pathogenic variation
THBD No pathogenic variation
MLPA Factor H operon No aberrations
Hematological Hemoglobin (mmol/l) 4.5 3.3 7.3 6.8–8.6
Platelet count (x109/l) 22 18 872 210–430
WBC count (x109/l) 15.5 29.0 12.9 5.0–17.0
Schizocytes (%) >5 >5 NA <0,5
Haptoglobin (g/l) Hemolytic Hemolytic 1.85a 0.3–1.6
LDH (U/l) 2285 6521 908 <250
Kidney Creatinine (μmol/l) 167 444 (PD) 470 (PD) 15–45
eGFR(ml/min/1.73 m2) 17 anuria anuria 80–120
BUN (mmol/l) 43.9 44.2 22.4 2.5–7.0
Brain MRI Diffusion restriction of the
deep white matter
consistent with metabolic
encephalopathy
NA NA
EEG No epileptic activity NA NA
Heart CK (U/l) 2743 8390 139a <170
Ntpro-BNP (pg/ml) NA >180,000 NA <320
Troponin T levels (ng/l) 557 23,444 508a <14
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described plasmid associated with extra intestinal virulence,
resulted in an increased association with HUS [8]. Only recent-
ly, Soysal et al. described the STEC serotype O80 as a new
therapeutic challenge in patients with STEC-HUS due to its
capacity to cause a bacteremia [8]. Furthermore, Espié et al.
described an outbreak of STEC serotypes O26 and O80 co-
infection related to unpasteurized cheese [6]. However, our pa-
tient had no bacteremia and no indication of co-infection, tested
with both fecal diagnostics and serological antibody assays
against both O157 and O26 lipopolysaccharide (Table 1).
Mariani-Kurkdjian et al. described the case of an adult male
with a severe episode of HUS caused by STEC O80:H2 con-
taining both Stx2d and the rare eae ξ variant like the strain
described above [7]. Similar to our case, the adult male patient
presented with afebrile convulsions followed by coma and,
after a few weeks, he developed bacteremia. This raised the
question if the O80 serotype may not be cleared rapidly, in
contrast to most other serotypes. Such a slow clearance would
make it more likely that the STEC found in our patient could
be the consequence of the gastro-intestinal infection three
months prior to presentation [8, 10].
Nowadays, in the majority of laboratories, STEC diagnostics
comprises PCR, culture, and/or enzyme immune-assays.
Obviously, these approaches could havemissed the identification
of the O80:H2 strain. Using additional molecular and serotyping
assays allows the detection of virulence factors and typing of the
Stx genes, both important to estimate the virulence of the strain.
Such additional diagnostic tests are relevant both for individual
patients as for public health to monitor new or rare serotypes that
cause severe HUS and emerge into the population [9].
It can be challenging to clinically differentiate between
STEC-HUS and aHUS due to similarity of symptoms.
Similar to our patient, in 6–10% of the children with STEC-
HUS there is no (bloody) diarrhea, whereas aHUS is preceded
by diarrhea in 25% of cases [11]. Since aHUS is merely a
Table 1 (continued)
Test At admission Most abnormal value At discharge Normal value
or range
Echo NA Left ventricular
dysfunction
Normal left
ventricular functiona
Pancreas Amylase (U/l) NA 1933 42a <105
Glucose (mmol/l) 9.9 30.7 6.2 4.0–5.6
Triglycerides (mmol/l) NA 14.17 4.92 0.8–2.0
Liver AST (U/l) 163 1020 114 <35
ALT (U/l) 62 480 144 <45
Gamma-GT (U/l) 6 1810 824 <55
Alkaline phosphatase (U/l) 205 1529 401 <115
Direct bilirubin (μmol/l) 4 326 35 <5
Ultrasound Edema around and
sludge inside gallbladder
Biopsy Cholestasis
aatA necessary for translocation of dispersin (Aap), ADAMTS13 a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13,
aggR transcriptional regulator aggR, aHUS atypical hemolytic uremic syndrome,ALTalanine transaminase,ASTaspartate transaminase,BUN blood urea
nitrogen,CFHR complement factor H-related proteins,CK creatine kinase,DGKE diacylglycerol kinase epsilon, eae E. coli attachment effacement gene
(intimin), EEG electroencephalogram, eGFR estimated glomerular filtration rate based on Schwartz estimation with k-value of 36.5, gammaGT gamma-
glutamyl transferase, IgA immunoglobulin A, IgG immunoglobulin G, IgM immunoglobulin M, LDH lactate dehydrogenase,MCPmembrane cofactor
protein, MLPA multiplex ligation-dependent probe amplification, MRI magnetic resonance imaging, NA not available, Ntpro-BNP N-terminal of the
prohormone brain natriuretic peptide, PCR polymerase chain reaction, PD peritoneal dialysis, STEC Shiga toxin-producing Escherichia coli, Stx1 Shiga
toxin 1, Stx2 Shiga toxin 2, THBD thrombomodulin, TTP thrombotic thrombocytopenic purpura, WBC white blood cell count, WGS whole genome
sequencing
a Two months after presentation
Fig. 1 Light microscopy on the liver biopsy (with hematoxylin and eosin
staining) revealed hepatocyte swelling and extensive signs of cholestasis
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diagnosis per exclusionem, it is essential to prove the absence
of an STEC infection [1, 12]. Even in cases without (bloody)
diarrhea and atypical presentations such as young age of the
patient, it is highly recommended to perform both fecal and
serological diagnostics in every HUS patient to exclude
STEC-HUS [12].
The treatment of STEC-HUS is merely symptomatic. A
topic of discussion remains the use of antibiotics to eradicate
STEC infection. Increased transcription, production, and re-
lease of shiga toxins, possibly aggravating HUS, can be in-
duced by antibiotics [13]. Soysal et al. studied in vitro effects
of different antibiotics on Stx production. Ceftriaxone, which
our patient received at presentation, seems to have no effect on
Stx production [8]. Another controversial topic in patients
with STEC-HUS is the use of eculizumab. Eculizumab, a
monoclonal antibody directed against complement C5, is
nowadays the standard treatment in patients with aHUS [14].
Some case series, among others Pape et al., reported better
outcome of STEC-HUS after eculizumab administration, par-
ticularly in neurologically affected STEC-HUS patients [3,
15]. However, Pape et al. also described the use of eculizumab
in patients with multi-organ failure, where it seems to be as-
sociated with a less favorable outcome [15]. Well-designed
and well-powered randomized controlled trials are needed to
shed light on the effect of eculizumab in STEC-HUS.
Extra-renal manifestations of TMA are not uncommon in
HUS. In 25% of HUS cases neurological involvement is not-
ed, other organs are affected less frequently [1, 3]. Although
severe multi-organ failure and especially liver failure is rarely
described in STEC-HUS, the highly severe disease presenta-
tion in our patient could partially be explained by the
(extraintestinal) virulence factors of this O80 strain.
However, in our patient, jaundice and liver failure evolved
2 weeks after one dose of eculizumab possibly indicating hep-
atotoxicity. This was recently described in five pediatric aHUS
patients [16]. Transient liver enzyme derangement was no-
ticed in these children 10–29 days after the first dose of
eculizumab with spontaneous resolution. The time pattern in
our patient, as described above, cannot rule out the hypothesis
that administration of eculizumab could have contributed to
liver failure in our patient.
In conclusion, we describe a severe case of STEC-HUS
caused by an unusual Stx2d-producing STEC O80:H2. This
resulted in an unusual and severe disease course, complicated
by multi-organ failure and central nervous system involve-
ment. This case emphasizes the importance of molecular and
serotyping assays to estimate the virulence of an STEC strain.
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